source
- AbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trialAbbVie’s Skyrizi-based combination therapy for inflammatory bowel disease worked better than Skyrizi alone in a mid-stage trial in Crohn’s disease, the company said Monday. The new product is coden…Endpoints · 1d ago↗ source
- Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweepDisc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…BioSpace · 1d ago↗ source
- Labcorp to acquire BioReference Health assets for $722M cashLabcorp and OPKO Health announced an agreement in which Labcorp will purchase select assets of BioReference Health, a subsidiary of OPKO. The assets include laboratory testing businesses focused o…